Clinical trials: Cervical Cancer Prevention
Vaccine Effectiveness, HPV Vaccination
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months…
- Conditions
- Vaccine Effectiveness, HPV Vaccination, Single Dose, Immunogenicity
- Trial name
- CervALONE (NCT07256912)
- Testing
- quadrivalent HPV vaccine
- Where
- Zambia
- Volunteers
- 1,266 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
Human Papillomavirus Vaccination, Cervical Cancer Prevention
Integrating HPV Education Into School Health Programs in Cambodia and Kenya
The Clinton Health Access Initiative conducted a mixed-methods, school-based interventional study in Cambodia and Kenya to evaluate whether integrating age-appropriate human papillomavirus (HPV) education into existing school…
- Trial name
- NCT07784283
- Testing
- Integrated HPV Education
- Where
- 5 sites in Cambodia, Kenya
- Volunteers
- 9,054 people, healthy volunteers welcome
- Sponsor
- Clinton Health Access Initiative Inc.
Cervical Cancer Prevention
Kupewa: Optimizing Implementation Strategies for Cervical Cancer Prevention
The goal of this clinical trial is identify an effective and implementable set of implementation strategies to increase cervical cancer prevention in Malawi. The main questions it aims to answer are: 1.
- Trial name
- NCT07015957
- Testing
- In-person training, Virtual training, Coaching
- Where
- Malawi
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- New York University
Cervical Cancer Prevention, Cervical Cancer
A Cervical Cancer Prevention Program in Kenya
Cervical cancer is caused by oncogenic, or "high-risk" (HR) human papillomavirus (HPV), and is the main cause of cancer-related death among Kenyan women.
- Trial name
- Merck-3 (NCT06411938)
- Testing
- High Risk HPV DNA Testing, Visual Inspection with acetic acid (VIA) and possible cervical biopsy, Gardisil-9
- Where
- Kenya
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Indiana University
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years.
- Trial name
- NCT03493542
- Testing
- V501
- Where
- China
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infection, HPV Vaccine
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity
This is a multi-center, open, prospective cohort study that aims to investigate the immunogenicity and immune persistence of two different domestically produced bivalent HPV vaccines compared with an imported HPV vaccine in women…
- Conditions
- HPV Infection, HPV Vaccine, Cervical Cancer Prevention
- Trial name
- NCT06137352
- Testing
- Follow up
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Maternity and Child Health Hospital
Cervical Cancer Squamous Cell, Human Papilloma Virus Infection
Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas
This study evaluates the women cervical samples through molecular tests in order to: 1. Deploy the test careHPV (hybrid capture test) in mobile unities of the Barretos Cancer Hospital to evaluate their performance;
- Conditions
- Cervical Cancer Squamous Cell, Human Papilloma Virus Infection, Human Papilloma Virus-Related Carcinoma, Prevention
- Trial name
- careHPV (NCT01539668)
- Where
- 2 sites in Brazil
- Volunteers
- 5,079 people, healthy volunteers welcome
- Sponsor
- Barretos Cancer Hospital